Promising combo tackles tough blood cancer in older patients
NCT ID NCT01880567
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 22 times
Summary
This study tests a combination of two drugs, ibrutinib and rituximab, in people with mantle cell lymphoma that has returned or not responded to treatment, as well as in older patients newly diagnosed with the disease. The goal is to see how well the drugs work together to shrink or control the cancer. About 113 participants are enrolled, and the study tracks tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.